Disruption of dopaminergic transmission remodels tripartite synapse morphology and astrocytic calcium activity within substantia nigra pars reticulata.
Identifieur interne : 000372 ( PubMed/Corpus ); précédent : 000371; suivant : 000373Disruption of dopaminergic transmission remodels tripartite synapse morphology and astrocytic calcium activity within substantia nigra pars reticulata.
Auteurs : Anthony Bosson ; Sylvie Boisseau ; Alain Buisson ; Marc Savasta ; Mireille AlbrieuxSource :
- Glia [ 1098-1136 ] ; 2015.
English descriptors
- KwdEn :
- Animals, Astrocytes (drug effects), Astrocytes (metabolism), Astrocytes (pathology), Benzazepines (pharmacology), Calcium (metabolism), Calcium Signaling (drug effects), Dopamine (metabolism), Glutamic Acid (metabolism), Male, Oxidopamine (toxicity), Pars Reticulata (cytology), Pars Reticulata (injuries), Pars Reticulata (metabolism), Pars Reticulata (pathology), Rats, Sulpiride (pharmacology), Synapses (metabolism), Synapses (pathology), Synaptic Transmission (drug effects).
- MESH :
- chemical , metabolism : Calcium, Dopamine, Glutamic Acid.
- chemical , pharmacology : Benzazepines, Sulpiride.
- cytology : Pars Reticulata.
- drug effects : Astrocytes, Calcium Signaling, Synaptic Transmission.
- injuries : Pars Reticulata.
- metabolism : Astrocytes, Pars Reticulata, Synapses.
- pathology : Astrocytes, Pars Reticulata, Synapses.
- chemical , toxicity : Oxidopamine.
- Animals, Male, Rats.
Abstract
The substantia nigra pars reticulata (SNr) is a major output nucleus of the basal ganglia circuitry particularly sensitive to pathological dopamine depletion. Indeed, hyperactivity of SNr neurons is known to be responsible for some motor disorders characteristic of Parkinson's disease. The neuronal processing of basal ganglia dysfunction is well understood but, paradoxically, the role of astrocytes in the regulation of SNr activity has rarely been considered. We thus investigated the influence of the disruption of dopaminergic transmission on plastic changes at tripartite glutamatergic synapses in the rat SNr and on astrocyte calcium activity. In 6-hydroxydopamine-lesioned rats, we observed structural plastic changes of tripartite glutamatergic synapses and perisynaptic astrocytic processes. These findings suggest that subthalamonigral synapses undergo morphological changes that accompany the pathophysiological processes of Parkinson's disease. The pharmacological blockade of dopaminergic transmission (with sulpiride and SCH-23390) increased astrocyte calcium excitability, synchrony and gap junction coupling within the SNr, suggesting a functional adaptation of astrocytes to dopamine transmission disruption in this output nucleus. This hyperactivity is partly reversed by subthalamic nucleus high-frequency stimulation which has emerged as an efficient symptomatic treatment for Parkinson's disease. Therefore, our results demonstrate structural and functional reshaping of neuronal and glial elements highlighting a functional plasticity of neuroglial interactions when dopamine transmission is disrupted.
DOI: 10.1002/glia.22777
PubMed: 25511180
Links to Exploration step
pubmed:25511180Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Disruption of dopaminergic transmission remodels tripartite synapse morphology and astrocytic calcium activity within substantia nigra pars reticulata.</title><author><name sortKey="Bosson, Anthony" sort="Bosson, Anthony" uniqKey="Bosson A" first="Anthony" last="Bosson">Anthony Bosson</name><affiliation><nlm:affiliation>Inserm, U836, 38000, Grenoble, France; Univ. Grenoble Alpes, Grenoble Institut des Neurosciences, 38000, Grenoble, France.</nlm:affiliation></affiliation></author><author><name sortKey="Boisseau, Sylvie" sort="Boisseau, Sylvie" uniqKey="Boisseau S" first="Sylvie" last="Boisseau">Sylvie Boisseau</name></author><author><name sortKey="Buisson, Alain" sort="Buisson, Alain" uniqKey="Buisson A" first="Alain" last="Buisson">Alain Buisson</name></author><author><name sortKey="Savasta, Marc" sort="Savasta, Marc" uniqKey="Savasta M" first="Marc" last="Savasta">Marc Savasta</name></author><author><name sortKey="Albrieux, Mireille" sort="Albrieux, Mireille" uniqKey="Albrieux M" first="Mireille" last="Albrieux">Mireille Albrieux</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25511180</idno><idno type="pmid">25511180</idno><idno type="doi">10.1002/glia.22777</idno><idno type="wicri:Area/PubMed/Corpus">000372</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000372</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Disruption of dopaminergic transmission remodels tripartite synapse morphology and astrocytic calcium activity within substantia nigra pars reticulata.</title><author><name sortKey="Bosson, Anthony" sort="Bosson, Anthony" uniqKey="Bosson A" first="Anthony" last="Bosson">Anthony Bosson</name><affiliation><nlm:affiliation>Inserm, U836, 38000, Grenoble, France; Univ. Grenoble Alpes, Grenoble Institut des Neurosciences, 38000, Grenoble, France.</nlm:affiliation></affiliation></author><author><name sortKey="Boisseau, Sylvie" sort="Boisseau, Sylvie" uniqKey="Boisseau S" first="Sylvie" last="Boisseau">Sylvie Boisseau</name></author><author><name sortKey="Buisson, Alain" sort="Buisson, Alain" uniqKey="Buisson A" first="Alain" last="Buisson">Alain Buisson</name></author><author><name sortKey="Savasta, Marc" sort="Savasta, Marc" uniqKey="Savasta M" first="Marc" last="Savasta">Marc Savasta</name></author><author><name sortKey="Albrieux, Mireille" sort="Albrieux, Mireille" uniqKey="Albrieux M" first="Mireille" last="Albrieux">Mireille Albrieux</name></author></analytic><series><title level="j">Glia</title><idno type="eISSN">1098-1136</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Astrocytes (drug effects)</term><term>Astrocytes (metabolism)</term><term>Astrocytes (pathology)</term><term>Benzazepines (pharmacology)</term><term>Calcium (metabolism)</term><term>Calcium Signaling (drug effects)</term><term>Dopamine (metabolism)</term><term>Glutamic Acid (metabolism)</term><term>Male</term><term>Oxidopamine (toxicity)</term><term>Pars Reticulata (cytology)</term><term>Pars Reticulata (injuries)</term><term>Pars Reticulata (metabolism)</term><term>Pars Reticulata (pathology)</term><term>Rats</term><term>Sulpiride (pharmacology)</term><term>Synapses (metabolism)</term><term>Synapses (pathology)</term><term>Synaptic Transmission (drug effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Calcium</term><term>Dopamine</term><term>Glutamic Acid</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Benzazepines</term><term>Sulpiride</term></keywords><keywords scheme="MESH" qualifier="cytology" xml:lang="en"><term>Pars Reticulata</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Astrocytes</term><term>Calcium Signaling</term><term>Synaptic Transmission</term></keywords><keywords scheme="MESH" qualifier="injuries" xml:lang="en"><term>Pars Reticulata</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Astrocytes</term><term>Pars Reticulata</term><term>Synapses</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Astrocytes</term><term>Pars Reticulata</term><term>Synapses</term></keywords><keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en"><term>Oxidopamine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Male</term><term>Rats</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The substantia nigra pars reticulata (SNr) is a major output nucleus of the basal ganglia circuitry particularly sensitive to pathological dopamine depletion. Indeed, hyperactivity of SNr neurons is known to be responsible for some motor disorders characteristic of Parkinson's disease. The neuronal processing of basal ganglia dysfunction is well understood but, paradoxically, the role of astrocytes in the regulation of SNr activity has rarely been considered. We thus investigated the influence of the disruption of dopaminergic transmission on plastic changes at tripartite glutamatergic synapses in the rat SNr and on astrocyte calcium activity. In 6-hydroxydopamine-lesioned rats, we observed structural plastic changes of tripartite glutamatergic synapses and perisynaptic astrocytic processes. These findings suggest that subthalamonigral synapses undergo morphological changes that accompany the pathophysiological processes of Parkinson's disease. The pharmacological blockade of dopaminergic transmission (with sulpiride and SCH-23390) increased astrocyte calcium excitability, synchrony and gap junction coupling within the SNr, suggesting a functional adaptation of astrocytes to dopamine transmission disruption in this output nucleus. This hyperactivity is partly reversed by subthalamic nucleus high-frequency stimulation which has emerged as an efficient symptomatic treatment for Parkinson's disease. Therefore, our results demonstrate structural and functional reshaping of neuronal and glial elements highlighting a functional plasticity of neuroglial interactions when dopamine transmission is disrupted.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25511180</PMID><DateCreated><Year>2015</Year><Month>02</Month><Day>16</Day></DateCreated><DateCompleted><Year>2015</Year><Month>10</Month><Day>29</Day></DateCompleted><DateRevised><Year>2015</Year><Month>02</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-1136</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><Issue>4</Issue><PubDate><Year>2015</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Glia</Title><ISOAbbreviation>Glia</ISOAbbreviation></Journal><ArticleTitle>Disruption of dopaminergic transmission remodels tripartite synapse morphology and astrocytic calcium activity within substantia nigra pars reticulata.</ArticleTitle><Pagination><MedlinePgn>673-83</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/glia.22777</ELocationID><Abstract><AbstractText>The substantia nigra pars reticulata (SNr) is a major output nucleus of the basal ganglia circuitry particularly sensitive to pathological dopamine depletion. Indeed, hyperactivity of SNr neurons is known to be responsible for some motor disorders characteristic of Parkinson's disease. The neuronal processing of basal ganglia dysfunction is well understood but, paradoxically, the role of astrocytes in the regulation of SNr activity has rarely been considered. We thus investigated the influence of the disruption of dopaminergic transmission on plastic changes at tripartite glutamatergic synapses in the rat SNr and on astrocyte calcium activity. In 6-hydroxydopamine-lesioned rats, we observed structural plastic changes of tripartite glutamatergic synapses and perisynaptic astrocytic processes. These findings suggest that subthalamonigral synapses undergo morphological changes that accompany the pathophysiological processes of Parkinson's disease. The pharmacological blockade of dopaminergic transmission (with sulpiride and SCH-23390) increased astrocyte calcium excitability, synchrony and gap junction coupling within the SNr, suggesting a functional adaptation of astrocytes to dopamine transmission disruption in this output nucleus. This hyperactivity is partly reversed by subthalamic nucleus high-frequency stimulation which has emerged as an efficient symptomatic treatment for Parkinson's disease. Therefore, our results demonstrate structural and functional reshaping of neuronal and glial elements highlighting a functional plasticity of neuroglial interactions when dopamine transmission is disrupted.</AbstractText><CopyrightInformation>© 2014 Wiley Periodicals, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bosson</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Inserm, U836, 38000, Grenoble, France; Univ. Grenoble Alpes, Grenoble Institut des Neurosciences, 38000, Grenoble, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boisseau</LastName><ForeName>Sylvie</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Buisson</LastName><ForeName>Alain</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Savasta</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Albrieux</LastName><ForeName>Mireille</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Glia</MedlineTA><NlmUniqueID>8806785</NlmUniqueID><ISSNLinking>0894-1491</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001552">Benzazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C534628">SCH 23390</NameOfSubstance></Chemical><Chemical><RegistryNumber>3KX376GY7L</RegistryNumber><NameOfSubstance UI="D018698">Glutamic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>7MNE9M8287</RegistryNumber><NameOfSubstance UI="D013469">Sulpiride</NameOfSubstance></Chemical><Chemical><RegistryNumber>8HW4YBZ748</RegistryNumber><NameOfSubstance UI="D016627">Oxidopamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001552" MajorTopicYN="N">Benzazepines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020013" MajorTopicYN="N">Calcium Signaling</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018698" MajorTopicYN="N">Glutamic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016627" MajorTopicYN="N">Oxidopamine</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065841" MajorTopicYN="N">Pars Reticulata</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000293" MajorTopicYN="N">injuries</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013469" MajorTopicYN="N">Sulpiride</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DBS</Keyword><Keyword MajorTopicYN="N">Parkinson</Keyword><Keyword MajorTopicYN="N">astrocyte</Keyword><Keyword MajorTopicYN="N">calcium</Keyword><Keyword MajorTopicYN="N">dopamine</Keyword><Keyword MajorTopicYN="N">synchrony</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>05</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>12</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25511180</ArticleId><ArticleId IdType="doi">10.1002/glia.22777</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000372 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000372 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:25511180
|texte= Disruption of dopaminergic transmission remodels tripartite synapse morphology and astrocytic calcium activity within substantia nigra pars reticulata.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:25511180" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |